Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Subependymal giant cell astrocytoma secondary prevention
Introduction
Overview
Overview
Effective measures for the secondary prevention of subependymal giant cell astrocytoma include brain imaging, preferably magnetic resonance imaging with and without contrast, which should be performed every 1 to 3 years until the age of 25 years in every patient with tuberous sclerosis.
Secondary Prevention
Secondary Prevention
Effective measures for the secondary prevention of subependymal giant cell astrocytoma include:[1]
- Brain imaging, preferably magnetic resonance imaging with and without contrast, should be performed every 1 to 3 years until the age of 25 years in every patient with tuberous sclerosis.
- Follow-up magnetic resonance imaging may not be needed every 3 years, but intervals may be prolonged in the presence of a stable lesion and a stable patient.
- Screening and follow-up scans frequency should be tailored according to various clinical factors.
- New onset of symptoms such as headache, visual complaints, nausea, vomiting, or increase in seizure activity should warrant an earlier MRI scan.
- Similarly, a growing subependymal giant cell astrocytoma should prompt a more frequent clinical and radiological follow-up.
References
References
- β Roth, Jonathan; Roach, E. Steve; Bartels, Ute; JΓ³ΕΊwiak, Sergiusz; Koenig, Mary Kay; Weiner, Howard L.; Franz, David N.; Wang, Henry Z. (2013). “Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012”. Pediatric Neurology. 49 (6): 439β444. doi:10.1016/j.pediatrneurol.2013.08.017. ISSNΒ 0887-8994.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2], Ifeoma Odukwe, M.D. [3]